Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
SYNN | NSE | INR | Real-time | |
SYNNc1:NS | NSE | INR | Delayed | |
SYNNc2:NS | NSE | INR | Delayed | |
SYNN | BSE | INR | Delayed |
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Name | Age | Since | Title |
---|---|---|---|
Sharmila Abhay Karve | 57 | 2019 | Additional Independent Director |
Kiran Mazumdar-Shaw | 70 | 2011 | Non-Executive Chairperson |
Jonathan Brittan Hunt | 54 | 2016 | MD, CEO & Executive Director |
Kush M. Parmar | 44 | 2021 | Independent Non Executive Director |
Paul Frederick Blackburn | 70 | 2014 | Non-Executive Independent Director |
Vijay Kumar Kuchroo | 69 | 2017 | Independent Director |
Catherine Patricia Rosenberg | 63 | 2000 | Non-Executive Director |
Vinita Bali | 69 | 2017 | Lead Independent Director |
Sharmila Abhay Karve | 59 | 2019 | Additional Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review